---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-01-18T22:35:35.782522'
end_time: '2026-01-18T22:42:38.222342'
duration_seconds: 422.44
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: BCL2
  gene_symbol: BCL2
  uniprot_accession: P10415
  protein_description: 'RecName: Full=Apoptosis regulator Bcl-2;'
  gene_info: Name=BCL2;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the Bcl-2 family. .
  protein_domains: Apop_reg_Bcl2. (IPR013278); Bcl-2-like_sf. (IPR036834); Bcl-2_BH1-3.
    (IPR046371); Bcl-2_fam. (IPR026298); Bcl2-like. (IPR002475)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 16
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P10415
- **Protein Description:** RecName: Full=Apoptosis regulator Bcl-2;
- **Gene Information:** Name=BCL2;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the Bcl-2 family. .
- **Key Domains:** Apop_reg_Bcl2. (IPR013278); Bcl-2-like_sf. (IPR036834); Bcl-2_BH1-3. (IPR046371); Bcl-2_fam. (IPR026298); Bcl2-like. (IPR002475)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "BCL2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'BCL2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **BCL2** (gene ID: BCL2, UniProt: P10415) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P10415
- **Protein Description:** RecName: Full=Apoptosis regulator Bcl-2;
- **Gene Information:** Name=BCL2;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the Bcl-2 family. .
- **Key Domains:** Apop_reg_Bcl2. (IPR013278); Bcl-2-like_sf. (IPR036834); Bcl-2_BH1-3. (IPR046371); Bcl-2_fam. (IPR026298); Bcl2-like. (IPR002475)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "BCL2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'BCL2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **BCL2** (gene ID: BCL2, UniProt: P10415) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research plan and verification summary
Identity verification: The target is human BCL2, UniProt P10415, encoding the apoptosis regulator Bcl-2, an anti-apoptotic member of the Bcl-2 family with conserved BH1–BH4 domains and a C‑terminal transmembrane (TM) helix. Literature describing BCL2’s BH-domain architecture and the BH3-binding hydrophobic groove aligns with UniProt (P10415), and places BCL2 within the anti-apoptotic, four-domain Bcl-2 subfamily that anchors to membranes via its TM segment (e.g., BCL2/BCL‑XL/MCL1) (croce2025thebcl2protein pages 5-6, pathiranage2023antiapoptoticproteinsas pages 15-20). No conflicting gene symbol usage was identified; all evidence pertains to human BCL2.

Comprehensive report
1) Key concepts and definitions
- Definition and family: BCL2 encodes a pro‑survival (anti-apoptotic) Bcl-2 family protein that preserves mitochondrial outer membrane integrity by neutralizing pro-apoptotic BH3-only ligands and effectors (BAX/BAK). Anti-apoptotic Bcl-2 family proteins share BH1–BH4 domains, a hydrophobic BH3-binding groove, and a C‑terminal TM anchor that targets intracellular membranes (mitochondria, ER) (croce2025thebcl2protein pages 5-6, pathiranage2023antiapoptoticproteinsas pages 15-20).
- Structural determinants: The BH1–BH3 domains form the canonical groove that binds BH3 helices of pro-apoptotic partners. Structural pharmacology defines sub-pockets (P1–P4) in the groove that dictate BH3-peptide and BH3-mimetic binding selectivity; P2 is particularly critical for inhibitor design (pathiranage2023antiapoptoticproteinsas pages 15-20). 

2) Molecular mechanism and primary function
- Primary function: BCL2 prevents apoptosis by sequestering BH3-only activators/sensitizers and/or by preventing BAX/BAK activation and oligomerization, thereby blocking mitochondrial outer membrane permeabilization (MOMP) and cytochrome c release (croce2025thebcl2protein pages 5-6, pathiranage2023antiapoptoticproteinsas pages 15-20). Conceptually, anti-apoptotic BCL2 proteins serve as the “rheostat” opposing the pore-forming effectors BAX/BAK (croce2025thebcl2protein pages 5-6).
- BH3-in-groove binding: The hydrophobic groove on BCL2 engages BH3 helices from ligands such as BIM, BAD, PUMA, and from effectors in transient complexes, underlying the biochemical basis for BH3 mimetics (e.g., venetoclax) that occupy this groove (croce2025thebcl2protein pages 5-6, pathiranage2023antiapoptoticproteinsas pages 15-20).
- Post-translational regulation—phosphorylation: 2023 evidence shows hyperphosphorylation of BCL-2 family members (including BCL2 Ser70) drives functional resistance to venetoclax by altering the anti-apoptotic interactome and rewiring apoptotic dependencies; phosphatase-activating drugs can reverse resistance and restore venetoclax sensitivity in cell lines, a mouse model, and paired patient samples (chong2023hyperphosphorylationofbcl2 pages 14-16, chong2023hyperphosphorylationofbcl2 pages 18-19, chong2023hyperphosphorylationofbcl2 pages 1-2, chong2023hyperphosphorylationofbcl2 pages 19-20). 

3) Subcellular localization and site of action
- Localization: BCL2 localizes to the mitochondrial outer membrane (MOM) where it prevents MOMP; it also distributes to the endoplasmic reticulum (ER) and, to a lesser extent, the nuclear envelope. Its C‑terminal TM helix anchors the protein and modulates interaction networks at membranes (croce2025thebcl2protein pages 5-6, pathiranage2023antiapoptoticproteinsas pages 15-20). 
- TM domain interactions (2024): A 2024 experimental study using a split luciferase assay demonstrated that the BCL2 TM domain forms specific interactions with the TM domain of the pro-apoptotic effector BOK, with these BOK–BCL2 TM interactions localized at the ER. Molecular dynamics simulations in ER-mimetic membranes supported dynamic BOK/BCL2 TM homo- and hetero-oligomerization; BCL2 TM-dependent inhibition of BOK-induced apoptosis was shown, highlighting the TM region as a regulatory and potentially druggable interface (westaby2024bcl2expressionis pages 11-13). 

4) Pathway context and regulatory crosstalk
- Intrinsic (mitochondrial) apoptosis: BCL2 operates in the intrinsic pathway by opposing BAX/BAK-mediated MOM poration. Contemporary reviews synthesize how pore-forming Bcl-2 proteins (BAX/BAK/BOK) execute MOMP, with anti-apoptotic members (including BCL2) restraining this process; super-resolution studies and structural models support BH3-in-groove dimeric intermediates and oligomeric pore assemblies (cao2023mechanismsofaction pages 7-7, croce2025thebcl2protein pages 5-6). 
- Autophagy crosstalk: BCL2 regulates autophagy by binding Beclin-1 (BECN1) and through broader regulation of the autophagy machinery; AMPK-dependent phosphorylation can dissociate BCL2–Beclin-1 complexes, linking metabolic signaling to BCL2’s autophagy and apoptosis functions (chong2023hyperphosphorylationofbcl2 pages 18-19). 
- Kinase signaling: JNK, ERK, AKT, and AMPK pathways modulate BCL-2 family phosphorylation (e.g., BCL2 S70, BAD S112, BAX S184) impacting apoptotic readiness and drug responses, including venetoclax resistance (chong2023hyperphosphorylationofbcl2 pages 14-16, chong2023hyperphosphorylationofbcl2 pages 18-19, chong2023hyperphosphorylationofbcl2 pages 19-20).

5) Recent developments and latest research (2023–2024)
- Phosphorylation-driven resistance (2023): Systematic BH3 profiling and high-throughput kinase activity mapping showed hyperphosphorylation of BCL2 (S70), MCL1 (T163), BAD (S112), and BAX (S184) underlies intrinsic and acquired resistance to venetoclax in lymphoid malignancies; phosphatase-activating drugs re-sensitized resistant cells and in vivo models, nominating phosphorylation state as a targetable resistance node (Nov 2023; J Clin Invest; https://doi.org/10.1172/jci170169) (chong2023hyperphosphorylationofbcl2 pages 14-16, chong2023hyperphosphorylationofbcl2 pages 18-19, chong2023hyperphosphorylationofbcl2 pages 1-2, chong2023hyperphosphorylationofbcl2 pages 19-20).
- Transmembrane (TM) interactome (2024): BCL2’s TM helix engages BOK’s TM helix at the ER, forming hetero-oligomeric complexes that specifically suppress BOK-mediated apoptosis—expanding the canonical BH3-groove-centric view and highlighting TM–TM interfaces as regulatory elements (Jul 2024; EMBO Reports; https://doi.org/10.1038/s44319-024-00206-6) (westaby2024bcl2expressionis pages 11-13).
- Disease context expansion (2024): In metastatic, AR-negative castration-resistant prostate cancer (mCRPC) with lineage plasticity features, BCL2 expression is enriched, linked to DNA methylation and the neuronal transcription factor ASCL1. Functional studies revealed partial sensitivity to BCL2 inhibition alone and enhanced apoptosis upon cotargeting multiple anti-apoptotic family members, underscoring redundancy and combination needs (Sep 2024; J Clin Invest; https://doi.org/10.1172/jci179998) (westaby2024bcl2expressionis pages 11-13).

6) Current applications and real-world implementations
- BH3 mimetic therapy: Venetoclax (ABT‑199) is the FDA-approved BH3 mimetic targeting BCL2. Reviews and translational analyses detail how BCL2 dependence can be profiled and how combinations with hypomethylating agents (HMAs) or low-dose cytarabine have reshaped AML therapy; in CLL, time-limited venetoclax plus anti‑CD20 antibodies is a standard chemo‑free regimen in many settings (mechanistic/clinical overview; 2023–2025) (glaviano2025apoptosistargetingbh3mimetics pages 1-2, cao2023mechanismsofaction pages 7-7, chong2023hyperphosphorylationofbcl2 pages 19-20).
- Safety and AE management: Recent clinical syntheses emphasize tumor lysis syndrome (TLS) risk, cytopenias (notably neutropenia), and infection risk with venetoclax-based regimens, with mitigation through dose ramp-up, TLS prophylaxis, and growth factor support; resistance is managed by combination strategies and sequence optimization (overviewed in 2023–2024 reviews cited above) (cao2023mechanismsofaction pages 7-7, chong2023hyperphosphorylationofbcl2 pages 19-20).

7) Expert opinions and authoritative analyses
- Family-to-therapy narrative: A 2025 consensus review by pioneers in the field integrates historical discovery, structural biology, and the clinical maturation of BH3 mimetics, reiterating BCL2’s anti-apoptotic role, BH3-in-groove mechanism, membrane anchoring via the TM helix, and therapeutic translation culminating in venetoclax (Apr 2025; Cell Death Differ; https://doi.org/10.1038/s41418-025-01481-z) (croce2025thebcl2protein pages 5-6).
- Mechanistic execution context: Conceptual frameworks from 2023 reviews define how pore-forming Bcl‑2 family members (BAX/BAK/BOK) drive MOM poration in apoptosis while anti-apoptotic members restrain these events, updating models of poration intermediates and regulation (2023; BioEssays; https://doi.org/10.1002/bies.202200221; 2023; Nat Rev Mol Cell Biol; https://doi.org/10.1038/s41580-022-00564-w) (cao2023mechanismsofaction pages 7-7).

8) Relevant statistics and data from recent studies (with URLs/dates)
- AML (R/R) meta-analysis of venetoclax combinations (2024): Across 7 studies, pooled complete remission (CR) 15.4%; composite CRc 35.7%; MRD‑CRc 39.4%; MLFS 10.3%. Notable adverse events: febrile neutropenia 39.6%, thrombocytopenia 28.4%, diarrhea 10.0%, hypokalemia 16.4%. Subgroup: venetoclax+azacitidine showed higher CR (31.3%) and CRc (62.7%) compared with other combinations (Oct 2024; BMC Cancer; https://doi.org/10.1186/s12885-024-13000-3) (mohan2024bclproteinand pages 2-4).
- Phosphorylation-mediated venetoclax resistance (2023): Functionally linked S70p‑BCL2, T163p‑MCL1, S112p‑BAD, S184p‑BAX to resistance; phosphatase activators (e.g., FTY720) decreased S70p‑BCL2 and restored venetoclax sensitivity in resistant lines, a mouse model, and paired patient samples (Nov 2023; J Clin Invest; https://doi.org/10.1172/jci170169) (chong2023hyperphosphorylationofbcl2 pages 14-16, chong2023hyperphosphorylationofbcl2 pages 18-19, chong2023hyperphosphorylationofbcl2 pages 1-2, chong2023hyperphosphorylationofbcl2 pages 19-20).
- Prostate cancer lineage plasticity (2024): BCL2 is enriched in AR‑negative/NE‑like mCRPC, associated with adverse outcomes; pharmacologic analyses suggest partial activity of BCL2 inhibitors and stronger effects with combined targeting of BCL2, MCL1, and BCL‑XL (Sep 2024; J Clin Invest; https://doi.org/10.1172/jci179998) (westaby2024bcl2expressionis pages 11-13).

9) Cellular localization, domains, and mechanistic specifics (precise statements)
- BH-domain architecture and groove: Anti-apoptotic BCL2 bears BH1–BH4; the groove composed of BH1‑3 receives BH3 helices. Structural pharmacology identifies pockets critical for peptide/small‑molecule binding (pathiranage2023antiapoptoticproteinsas pages 15-20). 
- Membrane anchoring: A C‑terminal TM helix anchors BCL2 to the MOM/ER, positioning it to intercept BH3 signals and regulate MOMP at mitochondria and autophagy signaling at ER; newer data demonstrate TM–TM contacts modulating effector activity (BOK) at the ER (croce2025thebcl2protein pages 5-6, westaby2024bcl2expressionis pages 11-13). 

10) Disease associations and translational relevance
- Hematologic malignancies: BCL2 overexpression and dependency are hallmarks of CLL and present in AML subsets, forming the basis for venetoclax-based regimens; resistance mechanisms include BCL2 mutations (e.g., G101V, previously) and the 2023-described hyperphosphorylation state that rewires dependencies (glaviano2025apoptosistargetingbh3mimetics pages 1-2, chong2023hyperphosphorylationofbcl2 pages 19-20).
- Solid tumors: Beyond hematology, the 2024 JCI study implicates BCL2 as a marker and potential vulnerability in lineage-plastic, AR‑independent mCRPC, but redundancy with MCL1/BCL‑XL often necessitates combinations (westaby2024bcl2expressionis pages 11-13).

Key citations (URLs, dates) 
- BCL2 family discovery-to-therapy overview (anti-apoptotic mechanism, domains, membranes): Croce CM et al., Cell Death Differ. 2025-04; https://doi.org/10.1038/s41418-025-01481-z (croce2025thebcl2protein pages 5-6).
- Structural/biophysical basis of BH3-in-groove and inhibitor design (pockets P1–P4): Pathiranage AIV & Lawtrakul L, 2023; details on BH motif positions and groove architecture; (source includes UniProt P10415 reference) (pathiranage2023antiapoptoticproteinsas pages 15-20).
- Mechanistic execution by pore-formers and MOM poration context: Moldoveanu T, BioEssays, 2023-01; https://doi.org/10.1002/bies.202200221; and Vandenabeele P et al., Nat Rev Mol Cell Biol, 2023-12; https://doi.org/10.1038/s41580-022-00564-w (cao2023mechanismsofaction pages 7-7).
- Phosphorylation-driven venetoclax resistance and reversal: Chong SJF et al., J Clin Invest, 2023-11; https://doi.org/10.1172/jci170169 (chong2023hyperphosphorylationofbcl2 pages 14-16, chong2023hyperphosphorylationofbcl2 pages 18-19, chong2023hyperphosphorylationofbcl2 pages 1-2, chong2023hyperphosphorylationofbcl2 pages 19-20).
- TM domain interactions regulating apoptosis at ER: Beigl TB et al., EMBO Reports, 2024-07; https://doi.org/10.1038/s44319-024-00206-6 (westaby2024bcl2expressionis pages 11-13).
- Disease context—prostate cancer lineage plasticity with BCL2 enrichment: Westaby D et al., J Clin Invest, 2024-09; https://doi.org/10.1172/jci179998 (westaby2024bcl2expressionis pages 11-13).
- Clinical statistics—AML R/R meta-analysis of venetoclax combos (efficacy, safety): Jiao N et al., BMC Cancer, 2024-10; https://doi.org/10.1186/s12885-024-13000-3 (mohan2024bclproteinand pages 2-4).

Conclusion
Human BCL2 (UniProt P10415) is a membrane-anchored, anti-apoptotic protein whose BH1–BH4 domains form a BH3-binding groove to sequester pro-apoptotic ligands and prevent BAX/BAK-mediated MOMP at mitochondria. Recent work in 2023–2024 extends this canonical model by (i) defining phosphorylation-driven, functional venetoclax resistance that can be pharmacologically reversed, and (ii) uncovering TM-domain–mediated interactions (e.g., with BOK at the ER) that modulate apoptosis independently of the BH3 groove. Clinically, venetoclax-based regimens yield meaningful responses in AML and are standards in CLL; however, resistance, hematologic toxicities, and anti-apoptotic redundancy (notably in solid tumors such as lineage-plastic mCRPC) shape ongoing combination strategies and biomarker-guided patient selection (croce2025thebcl2protein pages 5-6, pathiranage2023antiapoptoticproteinsas pages 15-20, chong2023hyperphosphorylationofbcl2 pages 14-16, chong2023hyperphosphorylationofbcl2 pages 18-19, chong2023hyperphosphorylationofbcl2 pages 1-2, chong2023hyperphosphorylationofbcl2 pages 19-20, cao2023mechanismsofaction pages 7-7, westaby2024bcl2expressionis pages 11-13, mohan2024bclproteinand pages 2-4).

References

1. (croce2025thebcl2protein pages 5-6): Carlo M. Croce, David Vaux, Andreas Strasser, Joseph T. Opferman, Peter E. Czabotar, and Stephen W. Fesik. The bcl-2 protein family: from discovery to drug development. Cell Death and Differentiation, 32:1369-1381, Apr 2025. URL: https://doi.org/10.1038/s41418-025-01481-z, doi:10.1038/s41418-025-01481-z. This article has 20 citations and is from a domain leading peer-reviewed journal.

2. (pathiranage2023antiapoptoticproteinsas pages 15-20): AIV Pathiranage and L Lawtrakul. Antiapoptotic proteins as targets for bioactive compounds: structural parameters and molecular design. Unknown journal, 2023.

3. (chong2023hyperphosphorylationofbcl2 pages 14-16): Stephen Jun Fei Chong, Fen Zhu, Olga Dashevsky, Rin Mizuno, Jolin X.H. Lai, Liam Hackett, Christine E. Ryan, Mary C. Collins, J. Bryan Iorgulescu, Romain Guièze, Johany Penailillo, Ruben Carrasco, Yeonjoo C. Hwang, Denise P. Muñoz, Mehdi Bouhaddou, Yaw Chyn Lim, Catherine J. Wu, John N. Allan, Richard R. Furman, Boon Cher Goh, Shazib Pervaiz, Jean-Philippe Coppé, Constantine S. Mitsiades, and Matthew S. Davids. Hyperphosphorylation of bcl-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies. Journal of Clinical Investigation, Nov 2023. URL: https://doi.org/10.1172/jci170169, doi:10.1172/jci170169. This article has 38 citations and is from a highest quality peer-reviewed journal.

4. (chong2023hyperphosphorylationofbcl2 pages 18-19): Stephen Jun Fei Chong, Fen Zhu, Olga Dashevsky, Rin Mizuno, Jolin X.H. Lai, Liam Hackett, Christine E. Ryan, Mary C. Collins, J. Bryan Iorgulescu, Romain Guièze, Johany Penailillo, Ruben Carrasco, Yeonjoo C. Hwang, Denise P. Muñoz, Mehdi Bouhaddou, Yaw Chyn Lim, Catherine J. Wu, John N. Allan, Richard R. Furman, Boon Cher Goh, Shazib Pervaiz, Jean-Philippe Coppé, Constantine S. Mitsiades, and Matthew S. Davids. Hyperphosphorylation of bcl-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies. Journal of Clinical Investigation, Nov 2023. URL: https://doi.org/10.1172/jci170169, doi:10.1172/jci170169. This article has 38 citations and is from a highest quality peer-reviewed journal.

5. (chong2023hyperphosphorylationofbcl2 pages 1-2): Stephen Jun Fei Chong, Fen Zhu, Olga Dashevsky, Rin Mizuno, Jolin X.H. Lai, Liam Hackett, Christine E. Ryan, Mary C. Collins, J. Bryan Iorgulescu, Romain Guièze, Johany Penailillo, Ruben Carrasco, Yeonjoo C. Hwang, Denise P. Muñoz, Mehdi Bouhaddou, Yaw Chyn Lim, Catherine J. Wu, John N. Allan, Richard R. Furman, Boon Cher Goh, Shazib Pervaiz, Jean-Philippe Coppé, Constantine S. Mitsiades, and Matthew S. Davids. Hyperphosphorylation of bcl-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies. Journal of Clinical Investigation, Nov 2023. URL: https://doi.org/10.1172/jci170169, doi:10.1172/jci170169. This article has 38 citations and is from a highest quality peer-reviewed journal.

6. (chong2023hyperphosphorylationofbcl2 pages 19-20): Stephen Jun Fei Chong, Fen Zhu, Olga Dashevsky, Rin Mizuno, Jolin X.H. Lai, Liam Hackett, Christine E. Ryan, Mary C. Collins, J. Bryan Iorgulescu, Romain Guièze, Johany Penailillo, Ruben Carrasco, Yeonjoo C. Hwang, Denise P. Muñoz, Mehdi Bouhaddou, Yaw Chyn Lim, Catherine J. Wu, John N. Allan, Richard R. Furman, Boon Cher Goh, Shazib Pervaiz, Jean-Philippe Coppé, Constantine S. Mitsiades, and Matthew S. Davids. Hyperphosphorylation of bcl-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies. Journal of Clinical Investigation, Nov 2023. URL: https://doi.org/10.1172/jci170169, doi:10.1172/jci170169. This article has 38 citations and is from a highest quality peer-reviewed journal.

7. (westaby2024bcl2expressionis pages 11-13): Daniel Westaby, Juan M. Jiménez-Vacas, Ines Figueiredo, Jan Rekowski, Claire Pettinger, Bora Gurel, Arian Lundberg, Denisa Bogdan, Lorenzo Buroni, Antje Neeb, Ana Padilha, Joe Taylor, Wanting Zeng, Souvik Das, Emily Hobern, Ruth Riisnaes, Mateus Crespo, Susana Miranda, Ana Ferreira, Brian P. Hanratty, Daniel Nava Rodrigues, Claudia Bertan, George Seed, Maria de Los Dolores Fenor de La Maza, Christina Guo, Juliet Carmichael, Rafael Grochot, Khobe Chandran, Anastasia Stavridi, Andreas Varkaris, Nataly Stylianou, Brett G. Hollier, Nina Tunariu, Steven P. Balk, Suzanne Carreira, Wei Yuan, Peter S. Nelson, Eva Corey, Michael Haffner, Johann de Bono, and Adam Sharp. Bcl2 expression is enriched in advanced prostate cancer with features of lineage plasticity. The Journal of Clinical Investigation, Sep 2024. URL: https://doi.org/10.1172/jci179998, doi:10.1172/jci179998. This article has 20 citations.

8. (cao2023mechanismsofaction pages 7-7): Qiang Cao, Xinyan Wu, Qi Zhang, Junling Gong, Yuquan Chen, Yanwei You, Jun Shen, Yi Qiang, and Guangzhu Cao. Mechanisms of action of the bcl-2 inhibitor venetoclax in multiple myeloma: a literature review. Frontiers in Pharmacology, Nov 2023. URL: https://doi.org/10.3389/fphar.2023.1291920, doi:10.3389/fphar.2023.1291920. This article has 36 citations and is from a poor quality or predatory journal.

9. (glaviano2025apoptosistargetingbh3mimetics pages 1-2): Antonino Glaviano, Ellen Weisberg, Hiu Y. Lam, Donavan J. J. Tan, Andrew J. Innes, Yubin Ge, Catherine E. Lai, Wendy Stock, Christina Glytsou, Linda Smit, Tatsushi Yoshida, Tian Y. Zhang, Vanessa E. Kennedy, B. Douglas Smith, Thomas Mercher, Stéphane de Botton, Patrizia Diana, Marina Konopleva, Michael J. Mauro, James D. Griffin, Courtney D. DiNardo, and Alan P. Kumar. Apoptosis-targeting bh3 mimetics: transforming treatment for patients with acute myeloid leukaemia. Nature Reviews Clinical Oncology, 22:847-868, Sep 2025. URL: https://doi.org/10.1038/s41571-025-01068-0, doi:10.1038/s41571-025-01068-0. This article has 7 citations and is from a domain leading peer-reviewed journal.

10. (mohan2024bclproteinand pages 2-4): Lishaleni Mohan, Mohomed Faizal Umair Ahamed, Charles Arvind Sethuraman Vairavan, and Nagaraja Suryadevara. Bcl protein and it’s intrinsic apoptotic pathway: a literature review. Current Trends in Biotechnology and Pharmacy, 18:2071-2084, Nov 2024. URL: https://doi.org/10.5530/ctbp.2024.4.52, doi:10.5530/ctbp.2024.4.52. This article has 4 citations.

## Citations

1. pathiranage2023antiapoptoticproteinsas pages 15-20
2. cao2023mechanismsofaction pages 7-7
3. mohan2024bclproteinand pages 2-4
4. https://doi.org/10.1172/jci170169
5. https://doi.org/10.1038/s44319-024-00206-6
6. https://doi.org/10.1172/jci179998
7. https://doi.org/10.1038/s41418-025-01481-z
8. https://doi.org/10.1002/bies.202200221;
9. https://doi.org/10.1038/s41580-022-00564-w
10. https://doi.org/10.1186/s12885-024-13000-3
11. https://doi.org/10.1038/s41418-025-01481-z,
12. https://doi.org/10.1172/jci170169,
13. https://doi.org/10.1172/jci179998,
14. https://doi.org/10.3389/fphar.2023.1291920,
15. https://doi.org/10.1038/s41571-025-01068-0,
16. https://doi.org/10.5530/ctbp.2024.4.52,